University of Crete (UOC)
Μελέτη του γονιδίου PRAME (εκλεκτικά εκφραζόμενου αντιγόνου μελανώματος) και του γονιδίου WT1 (Wilms' Tumour 1) σε αιματολογικές κακοήθειες της παιδικής ηλικίας
Abstract
dc:descriptionPRAME gene was initially isolated as human melanoma antigen, identified by cytotoxic T-cells. This gene is found to be expressed at low levels in normal tissues, while increased PRAME expression has been reported in solid tumours and haematological malignancies. WT1 gene was firstly identified in a patient with Wilms’ tumour. It is expressed at low levels in normal bone marrow and peripheral blood and it has also been found at high levels in almost all adult haematological malignancies. The expression of the above mentioned genes has been inadequately studied in childhood acute leukaemia. The aim of this study is the quantitative evaluation of PRAME and WT1 expression in bone marrow samples from newly diagnosed children with acute leukaemia with the use of RT-PCR. It is also aimed to correlate these genes expression with known prognostic factors as well as with the outcome of the disease. Bone marrow blasts from 17 children with acute leukaemia (11 ALL, 4 AML, 1 AML secondary to MDS, 1 ALL at relapse) were studied at diagnosis. Bone marrow samples from seven children with non-malignant haematological diseases or solid tumours without bone marrow infiltration were used as control group. In addition, K562 cell line was the positive control. Total RNA was isolated from bone marrow samples and reverse transcription and RT- PCR were performed. PRAME expression was calculated relatively to K562 values. WT1 values obtained were normalized with respect to the number of ABL transcripts. PRAME levels were found undetectable or extremely low in the control group. The mean PRAME relative expression detected in the control group was 0.11±0.06x10⁻⁴ (range 0-0.46x10⁻⁴). Samples were considered positive for PRAME expression if their expression level was one log higher than the mean level of expression reported for the control group. The quantitative assessment in the whole group of children with acute leukaemia at diagnosis or relapse showed a mean relative PRAME expression of 7.57±4.04x10⁻⁴ (range 0-67.2x10⁻⁴). Nine (3 AML, 6 ALL) of the 17 patients (52.9%) expressed high levels of PRAME [mean 14.3±2.9x10⁻⁴ (range 1.12-67.2x10⁻⁴)]. PRAME expression levels in the whole group of children with acute leukaemia compared to the PRAME positive patients, as well as between PRAME positive and PRAME negative patients were found to be statistically significant (p=0.049, p=0.0001, respectively). WT1 levels were found to be extremely low or undetectable in the control group. The mean number of WT1 copies/10⁴ ABL copies detected in the control group was 80.2±25.6 (range 0.1-178). Samples were considered WT1 positive if their expression level was one log higher than the mean number of WT1 copies/104 ABL copies of the control group. K562 cell line had high WT1 expression levels (7896 WT1 copies/10⁴ ABL copies). The expression of WT1 in 14 children with acute leukaemia at diagnosis was analyzed. The quantitative assessment in the whole group of patients with acute leukaemia reported a mean WT1 copy number of 1559.71±810.11 WT1 copies/10⁴ ABL copies (range 15-10542). Five (2 ALL, 3 AML) of the 14 patients (35.7%) expressed high levels of WT1 with a mean number of 4250±1776.41 WT1 copies/10⁴ ABL copies (range 977-10542). WT1 expression levels in WT1 positive patients compared to controls as well as in WT1 positive and WT1 negative patients were found to be statistically significant (p=0.03, p=0.01 respectively). Significant amounts of PRAME mRNA were reported for the 52.9% of children with acute leukaemia at diagnosis studied. No important correlation could be found between PRAME expression and clinical characteristics such as age, sex, initial white blood cell count, response to therapy, or progression free and overall survival. In this study, WT1 expression in control bone marrow samples was found to be at low levels. It was shown that significant levels of WT1 are expressed in 35.7% of children with newly diagnosed acute leukaemia. All but one of the WT1 positive patients had an unfavourable clinical outcome. The majority of the WT1 negative patients has achieved complete remission. Six out of the nine (66%) patients that have been reported as WT1 negative were found to be PRAME positive. Respectively, two out of the five WT1 positive patients had undetectable PRAME mRNA levels. The fact that the two genes are not co-expressed in the same patient, points towards a possible combination of PRAME and WT1 in order to better detect pending relapses. In this study, overexpression of PRAME and WT1 was detected in a significant percentage of children with acute leukaemia at diagnosis, indicating that these genes could be used as molecular markers in childhood acute leukaemia.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Spanaki, Adriani
- Σπανάκη, Αδριανή
Subjects
dc:subject × 17Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/15756